Education
About Us
Working with TipRanks
Follow Us
BiomX (PHGE)
:PHGE
Earnings Data
Report Date
Apr 01, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-5.06Last Year’s EPS
-6.27Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and positive regulatory feedback which provides a strong outlook for future developments. However, financial challenges and regulatory holds present ongoing risks. Optimism in phage therapy's future and strategic plans for BX011 and BX004 suggest a cautiously positive sentiment.Company Guidance
BX004 Phase IIb Trial Progress and FDA Feedback
The BX004 program for cystic fibrosis patients showed significant progress with first patient dosing in the Phase IIb trial. Despite a clinical hold on U.S. trial sites due to a third-party nebulizer device, the European trial continues uninterrupted. FDA feedback recognized the unmet need for treatments targeting chronic Pseudomonas aeruginosa infections and provided constructive guidance for development pathways, including Phase III criteria.
Positive FDA Feedback for BX011 in Diabetic Foot Infections
The FDA provided positive feedback on the development plan for BX011 targeting Staphylococcus aureus infections in diabetic foot infections (DFI). The program aims to provide an off-the-shelf formulation with potential for dual-use in combat-related wound infections, aligning with U.S. Defense Health Agency priorities. The FDA outlined a clear pathway toward a Biologics License Application without additional nonclinical studies, supporting the commercial opportunity.
Financial Management and Reduced Expenses
Research and development expenses decreased to $6.1 million in Q3 2025 from $7.3 million in Q3 2024, attributed to workforce reduction and lower rent expenses. General and administrative expenses also decreased to $2.4 million from $3.2 million. BiomX estimates its cash reserves are sufficient to fund operations into Q1 2026.
PHGE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PHGE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 12, 2025 | $7.29 | $7.15 | -1.92% |
Aug 13, 2025 | $10.68 | $9.43 | -11.70% |
May 15, 2025 | $10.39 | $10.71 | +3.08% |
Mar 25, 2025 | $11.97 | $11.11 | -7.18% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does BiomX (PHGE) report earnings?
BiomX (PHGE) is schdueled to report earning on Apr 01, 2026, Before Open (Confirmed).
What is BiomX (PHGE) earnings time?
BiomX (PHGE) earnings time is at Apr 01, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PHGE EPS forecast?
PHGE EPS forecast for the fiscal quarter 2025 (Q4) is -5.06.